Screener
Sionna Therapeutics SION Net Income
Net Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Sionna Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Sionna Therapeutics’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 7:17 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-033876
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Interest income | 2,820 | 3,000 |
| Other income | — | 177 |
| Total other income | 2,820 | 3,177 |
| Net loss | $(26,779) | $(16,482) |
| Net loss per share, basic and diluted | $(0.60) | $(0.62) |
| Weighted-average common shares outstanding, basic and diluted | 44,921,984 | 26,596,059 |
| Comprehensive loss: | ||
| Net loss | $(26,779) | $(16,482) |
Item 1. Financial Statements
FAQ
- What is Sionna Therapeutics's net income?
- Sionna Therapeutics (SION) reported net income of -$26.78M in Q1 2026.
- How has Sionna Therapeutics's net income changed year-over-year?
- Sionna Therapeutics's net income decreased by 62.5% year-over-year, from -$16.48M to -$26.78M.
- What does net income mean?
- Net income as the starting point for the indirect method operating cash flow reconciliation.
Ask your AI about Sionna Therapeutics's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude